Tag Archives: IPF

October 11 2013 – UAB gets $9.7 million to find treatments for deadly lung disease pulmonary fibrosis

UAB gets $9.7 million to find treatments for deadly lung disease pulmonary fibrosis by Bob Shepard Grant will allow UAB researchers to study novel therapies for pulmonary fibrosis, a deadly lung disease with no approved treatments. The University of Alabama at … Continue reading

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Lungen Fibrose, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , , , , | Leave a comment

October 10 2013 – Finding cellular causes of lung-hardening disease

Medical Xpress)—Idiopathic Pulmonary Fibrosis, or IPF, is an incurable lung disease that, over time, turns healthy lung tissue into inflexible scar tissue – hardening the lungs and eventually causing respiratory distress and death. Currently, there is no cure. Phil Sannes, … Continue reading

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lungen Fibrose, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , , | Leave a comment

October 9 2013- Promedior Initiates Phase 2 Clinical Study of PRM-151 in Myelofibrosis

Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, announced today that it has initiated a Phase 2 clinical trial to evaluate PRM-151, its lead product candidate, in patients with myelofibrosis. Promedior is … Continue reading

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Lungen Fibrose, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , , , , | 1 Comment

October 3 2013 – Newly identified biomarkers help predict outcome in deadly lung disease

New Haven, Conn. – A Yale-led study has identified a gene expression profile that can predict outcomes and lead to better treatment for one of the most lethal lung diseases, idiopathic pulmonary fibrosis (IPF). The study appears in Science Translational … Continue reading

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Lungen Fibrose, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , , , | Leave a comment

September 29 2013 – Trial to determine if stem cells can help with rare lung disease

By Cindy Krischer Goodman cindykgoodman@gmail.com Jose Guzman began gasping for breath while using his treadmill on the lowest setting and knew something was wrong. His search for answers led him to the diagnosis of a rare lung disease with no … Continue reading

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Lungen Fibrose, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , , | Leave a comment

September 28 2013 – Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future

Abstract During the past decade important progress has been made regarding the pathogenesis of idiopathic pulmonary fibrosis (IPF), which is the most devastating form of idiopathic interstitial pneumonia with a median survival of 3 years. The knowledge gained has been … Continue reading

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Lungen Fibrose, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , , | Leave a comment

September 2 2013 – New pathway to treat colorectal cancer, pulmonary fibrosis

Israel researchers uncover secrets of how a certain white blood cell can flip from being a ‘good guy’ to a ‘bad guy’ in diseases with no current cure. Doctoral student Danielle Karo-Atar studying macrophages at Tel Aviv University. A type … Continue reading

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Lungen Fibrose, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , , | Leave a comment

September 2 2013 – Boehringer Ingelheim to present highly anticipated data from landmark TIOSPIR™ trial, and their respiratory pipeline products in COPD, asthma, IPF and lung cancer at ERS 2013

INGELHEIM, Germany–(BUSINESS WIRE)– For media outside the UK, US and Canada Results of COPD Phase III landmark trial TIOSPIR™comparing safety and efficacy of SPIRIVA® Respimat® versus SPIRIVA® HandiHaler® Phase III trial results on investigational compound olodaterol* Respimat® as once-daily maintenance bronchodilator monotherapy in COPD … Continue reading

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , , , | Leave a comment

August 5 2013 – Oral N-acetylcysteine (NAC) reduces COPD exacerbations in RCT (Chest)

Oxidative stress (imbalance between oxidants and antioxidants) is part of the story of how COPD causes symptoms of cough and shortness of breath. Cigarette smoke is the main source of oxidation damage in the lungs leading to COPD, but even … Continue reading

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , , , , | Leave a comment

August 3 2013 – Ambrisentan found ineffective against idiopathic pulmonary fibrosis

1. Ambrisentan is ineffective in delaying disease progression in idiopathic pulmonary fibrosis (IPF). 2. Compared to placebo, Ambrisentan is associated with increased risk of disease progression and respiratory hospitalization. Evidence rating level: 1 (Excellent) Study rundown: Idiopathic Pulmonary Fibrosis (IPF) is … Continue reading

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , , | Leave a comment